TargetKelch-like ECH-associated protein 1/Nuclear factor erythroid 2-related factor 2(Human)
Senju Pharmaceutical Co.
US Patent
Senju Pharmaceutical Co.
US Patent
Affinity DataIC50: 0.140nMAssay Description:The inhibitory activity of each compound on the binding between NRF2 and KEAP1 was measured by bioluminescence resonance energy transfer (BRET) assay...More data for this Ligand-Target Pair
TargetKelch-like ECH-associated protein 1/Nuclear factor erythroid 2-related factor 2(Human)
Senju Pharmaceutical Co.
US Patent
Senju Pharmaceutical Co.
US Patent
Affinity DataIC50: 0.150nMAssay Description:In a first step, the Keapl /compound complex was prepared by addition of 100 nL of the compound by ECHO 555, followed by 5 pL aliquots of 2x Keapl. T...More data for this Ligand-Target Pair
TargetKelch-like ECH-associated protein 1/Nuclear factor erythroid 2-related factor 2(Human)
Senju Pharmaceutical Co.
US Patent
Senju Pharmaceutical Co.
US Patent
Affinity DataIC50: 0.150nMAssay Description:The inhibitory activity of each compound on the binding between NRF2 and KEAP1 was measured by bioluminescence resonance energy transfer (BRET) assay...More data for this Ligand-Target Pair
TargetKelch-like ECH-associated protein 1/Nuclear factor erythroid 2-related factor 2(Human)
Senju Pharmaceutical Co.
US Patent
Senju Pharmaceutical Co.
US Patent
Affinity DataIC50: 0.170nMAssay Description:The inhibitory activity of each compound on the binding between NRF2 and KEAP1 was measured by bioluminescence resonance energy transfer (BRET) assay...More data for this Ligand-Target Pair
TargetKelch-like ECH-associated protein 1/Nuclear factor erythroid 2-related factor 2(Human)
Senju Pharmaceutical Co.
US Patent
Senju Pharmaceutical Co.
US Patent
Affinity DataIC50: 0.170nMAssay Description:The inhibitory activity of each compound on the binding between NRF2 and KEAP1 was measured by bioluminescence resonance energy transfer (BRET) assay...More data for this Ligand-Target Pair
TargetKelch-like ECH-associated protein 1/Nuclear factor erythroid 2-related factor 2(Human)
Senju Pharmaceutical Co.
US Patent
Senju Pharmaceutical Co.
US Patent
Affinity DataIC50: 0.170nMAssay Description:The inhibitory activity of each compound on the binding between NRF2 and KEAP1 was measured by bioluminescence resonance energy transfer (BRET) assay...More data for this Ligand-Target Pair
TargetKelch-like ECH-associated protein 1/Nuclear factor erythroid 2-related factor 2(Human)
Senju Pharmaceutical Co.
US Patent
Senju Pharmaceutical Co.
US Patent
Affinity DataIC50: 0.190nMAssay Description:The inhibitory activity of each compound on the binding between NRF2 and KEAP1 was measured by bioluminescence resonance energy transfer (BRET) assay...More data for this Ligand-Target Pair
TargetKelch-like ECH-associated protein 1/Nuclear factor erythroid 2-related factor 2(Human)
Senju Pharmaceutical Co.
US Patent
Senju Pharmaceutical Co.
US Patent
Affinity DataIC50: 0.200nMAssay Description:In a first step, the Keapl /compound complex was prepared by addition of 100 nL of the compound by ECHO 555, followed by 5 pL aliquots of 2x Keapl. T...More data for this Ligand-Target Pair
TargetKelch-like ECH-associated protein 1/Nuclear factor erythroid 2-related factor 2(Human)
Senju Pharmaceutical Co.
US Patent
Senju Pharmaceutical Co.
US Patent
Affinity DataIC50: 0.200nMAssay Description:In a first step, the Keapl /compound complex was prepared by addition of 100 nL of the compound by ECHO 555, followed by 5 pL aliquots of 2x Keapl. T...More data for this Ligand-Target Pair
TargetKelch-like ECH-associated protein 1/Nuclear factor erythroid 2-related factor 2(Human)
Senju Pharmaceutical Co.
US Patent
Senju Pharmaceutical Co.
US Patent
Affinity DataIC50: 0.200nMAssay Description:The inhibitory activity of each compound on the binding between NRF2 and KEAP1 was measured by bioluminescence resonance energy transfer (BRET) assay...More data for this Ligand-Target Pair
TargetKelch-like ECH-associated protein 1/Nuclear factor erythroid 2-related factor 2(Human)
Senju Pharmaceutical Co.
US Patent
Senju Pharmaceutical Co.
US Patent
Affinity DataIC50: 0.230nMAssay Description:The inhibitory activity of each compound on the binding between NRF2 and KEAP1 was measured by bioluminescence resonance energy transfer (BRET) assay...More data for this Ligand-Target Pair
TargetKelch-like ECH-associated protein 1/Nuclear factor erythroid 2-related factor 2(Human)
Senju Pharmaceutical Co.
US Patent
Senju Pharmaceutical Co.
US Patent
Affinity DataIC50: 0.230nMAssay Description:The inhibitory activity of each compound on the binding between NRF2 and KEAP1 was measured by bioluminescence resonance energy transfer (BRET) assay...More data for this Ligand-Target Pair
TargetKelch-like ECH-associated protein 1/Nuclear factor erythroid 2-related factor 2(Human)
Senju Pharmaceutical Co.
US Patent
Senju Pharmaceutical Co.
US Patent
Affinity DataIC50: 0.240nMAssay Description:The inhibitory activity of each compound on the binding between NRF2 and KEAP1 was measured by bioluminescence resonance energy transfer (BRET) assay...More data for this Ligand-Target Pair
TargetKelch-like ECH-associated protein 1/Nuclear factor erythroid 2-related factor 2(Human)
Senju Pharmaceutical Co.
US Patent
Senju Pharmaceutical Co.
US Patent
Affinity DataIC50: 0.25nMAssay Description:In a first step, the Keapl /compound complex was prepared by addition of 100 nL of the compound by ECHO 555, followed by 5 pL aliquots of 2x Keapl. T...More data for this Ligand-Target Pair
TargetKelch-like ECH-associated protein 1/Nuclear factor erythroid 2-related factor 2(Human)
Senju Pharmaceutical Co.
US Patent
Senju Pharmaceutical Co.
US Patent
Affinity DataIC50: 0.25nMAssay Description:The inhibitory activity of each compound on the binding between NRF2 and KEAP1 was measured by bioluminescence resonance energy transfer (BRET) assay...More data for this Ligand-Target Pair
TargetKelch-like ECH-associated protein 1/Nuclear factor erythroid 2-related factor 2(Human)
Senju Pharmaceutical Co.
US Patent
Senju Pharmaceutical Co.
US Patent
Affinity DataIC50: 0.260nMAssay Description:Fluorescence polarization assay was performed on a Wallac Victor 3V multi-label counter/plate reader (PerkinElmer, Shelton, CT) using 484 nm excitati...More data for this Ligand-Target Pair
TargetKelch-like ECH-associated protein 1/Nuclear factor erythroid 2-related factor 2(Human)
Senju Pharmaceutical Co.
US Patent
Senju Pharmaceutical Co.
US Patent
Affinity DataIC50: 0.270nMAssay Description:The inhibitory activity of each compound on the binding between NRF2 and KEAP1 was measured by bioluminescence resonance energy transfer (BRET) assay...More data for this Ligand-Target Pair
TargetKelch-like ECH-associated protein 1/Nuclear factor erythroid 2-related factor 2(Human)
Senju Pharmaceutical Co.
US Patent
Senju Pharmaceutical Co.
US Patent
Affinity DataIC50: 0.270nMAssay Description:The inhibitory activity of each compound on the binding between NRF2 and KEAP1 was measured by bioluminescence resonance energy transfer (BRET) assay...More data for this Ligand-Target Pair
TargetKelch-like ECH-associated protein 1/Nuclear factor erythroid 2-related factor 2(Human)
Senju Pharmaceutical Co.
US Patent
Senju Pharmaceutical Co.
US Patent
Affinity DataIC50: 0.280nMAssay Description:The inhibitory activity of each compound on the binding between NRF2 and KEAP1 was measured by bioluminescence resonance energy transfer (BRET) assay...More data for this Ligand-Target Pair
TargetKelch-like ECH-associated protein 1/Nuclear factor erythroid 2-related factor 2(Human)
Senju Pharmaceutical Co.
US Patent
Senju Pharmaceutical Co.
US Patent
Affinity DataIC50: 0.300nMAssay Description:The inhibitory activity of each compound on the binding between NRF2 and KEAP1 was measured by bioluminescence resonance energy transfer (BRET) assay...More data for this Ligand-Target Pair
TargetKelch-like ECH-associated protein 1/Nuclear factor erythroid 2-related factor 2(Human)
Senju Pharmaceutical Co.
US Patent
Senju Pharmaceutical Co.
US Patent
Affinity DataIC50: 0.300nMAssay Description:The inhibitory activity of each compound on the binding between NRF2 and KEAP1 was measured by bioluminescence resonance energy transfer (BRET) assay...More data for this Ligand-Target Pair
TargetKelch-like ECH-associated protein 1/Nuclear factor erythroid 2-related factor 2(Human)
Senju Pharmaceutical Co.
US Patent
Senju Pharmaceutical Co.
US Patent
Affinity DataIC50: 0.310nMAssay Description:The inhibitory activity of each compound on the binding between NRF2 and KEAP1 was measured by bioluminescence resonance energy transfer (BRET) assay...More data for this Ligand-Target Pair
TargetKelch-like ECH-associated protein 1/Nuclear factor erythroid 2-related factor 2(Human)
Senju Pharmaceutical Co.
US Patent
Senju Pharmaceutical Co.
US Patent
Affinity DataIC50: 0.350nMAssay Description:In a first step, the Keapl /compound complex was prepared by addition of 100 nL of the compound by ECHO 555, followed by 5 pL aliquots of 2x Keapl. T...More data for this Ligand-Target Pair
TargetKelch-like ECH-associated protein 1/Nuclear factor erythroid 2-related factor 2(Human)
Senju Pharmaceutical Co.
US Patent
Senju Pharmaceutical Co.
US Patent
Affinity DataIC50: 0.350nMAssay Description:In a first step, the Keapl /compound complex was prepared by addition of 100 nL of the compound by ECHO 555, followed by 5 pL aliquots of 2x Keapl. T...More data for this Ligand-Target Pair
TargetKelch-like ECH-associated protein 1/Nuclear factor erythroid 2-related factor 2(Human)
Senju Pharmaceutical Co.
US Patent
Senju Pharmaceutical Co.
US Patent
Affinity DataIC50: 0.350nMAssay Description:In a first step, the Keapl /compound complex was prepared by addition of 100 nL of the compound by ECHO 555, followed by 5 pL aliquots of 2x Keapl. T...More data for this Ligand-Target Pair
TargetKelch-like ECH-associated protein 1/Nuclear factor erythroid 2-related factor 2(Human)
Senju Pharmaceutical Co.
US Patent
Senju Pharmaceutical Co.
US Patent
Affinity DataIC50: 0.350nMAssay Description:In a first step, the Keapl /compound complex was prepared by addition of 100 nL of the compound by ECHO 555, followed by 5 pL aliquots of 2x Keapl. T...More data for this Ligand-Target Pair
TargetKelch-like ECH-associated protein 1/Nuclear factor erythroid 2-related factor 2(Human)
Senju Pharmaceutical Co.
US Patent
Senju Pharmaceutical Co.
US Patent
Affinity DataIC50: 0.350nMAssay Description:In a first step, the Keapl /compound complex was prepared by addition of 100 nL of the compound by ECHO 555, followed by 5 pL aliquots of 2x Keapl. T...More data for this Ligand-Target Pair
TargetKelch-like ECH-associated protein 1/Nuclear factor erythroid 2-related factor 2(Human)
Senju Pharmaceutical Co.
US Patent
Senju Pharmaceutical Co.
US Patent
Affinity DataIC50: 0.360nMAssay Description:The inhibitory activity of each compound on the binding between NRF2 and KEAP1 was measured by bioluminescence resonance energy transfer (BRET) assay...More data for this Ligand-Target Pair
TargetKelch-like ECH-associated protein 1/Nuclear factor erythroid 2-related factor 2(Human)
Senju Pharmaceutical Co.
US Patent
Senju Pharmaceutical Co.
US Patent
Affinity DataIC50: 0.360nMAssay Description:The inhibitory activity of each compound on the binding between NRF2 and KEAP1 was measured by bioluminescence resonance energy transfer (BRET) assay...More data for this Ligand-Target Pair
TargetKelch-like ECH-associated protein 1/Nuclear factor erythroid 2-related factor 2(Human)
Senju Pharmaceutical Co.
US Patent
Senju Pharmaceutical Co.
US Patent
Affinity DataIC50: 0.390nMAssay Description:The inhibitory activity of each compound on the binding between NRF2 and KEAP1 was measured by bioluminescence resonance energy transfer (BRET) assay...More data for this Ligand-Target Pair
TargetKelch-like ECH-associated protein 1/Nuclear factor erythroid 2-related factor 2(Human)
Senju Pharmaceutical Co.
US Patent
Senju Pharmaceutical Co.
US Patent
Affinity DataIC50: 0.390nMAssay Description:The inhibitory activity of each compound on the binding between NRF2 and KEAP1 was measured by bioluminescence resonance energy transfer (BRET) assay...More data for this Ligand-Target Pair
TargetKelch-like ECH-associated protein 1/Nuclear factor erythroid 2-related factor 2(Human)
Senju Pharmaceutical Co.
US Patent
Senju Pharmaceutical Co.
US Patent
Affinity DataIC50: 0.410nMAssay Description:The inhibitory activity of each compound on the binding between NRF2 and KEAP1 was measured by bioluminescence resonance energy transfer (BRET) assay...More data for this Ligand-Target Pair
TargetKelch-like ECH-associated protein 1/Nuclear factor erythroid 2-related factor 2(Human)
Senju Pharmaceutical Co.
US Patent
Senju Pharmaceutical Co.
US Patent
Affinity DataIC50: 0.410nMAssay Description:The inhibitory activity of each compound on the binding between NRF2 and KEAP1 was measured by bioluminescence resonance energy transfer (BRET) assay...More data for this Ligand-Target Pair
TargetKelch-like ECH-associated protein 1/Nuclear factor erythroid 2-related factor 2(Human)
Senju Pharmaceutical Co.
US Patent
Senju Pharmaceutical Co.
US Patent
Affinity DataIC50: 0.450nMAssay Description:In a first step, the Keapl /compound complex was prepared by addition of 100 nL of the compound by ECHO 555, followed by 5 pL aliquots of 2x Keapl. T...More data for this Ligand-Target Pair
TargetKelch-like ECH-associated protein 1/Nuclear factor erythroid 2-related factor 2(Human)
Senju Pharmaceutical Co.
US Patent
Senju Pharmaceutical Co.
US Patent
Affinity DataIC50: 0.5nMAssay Description:The inhibitory activity of each compound on the binding between NRF2 and KEAP1 was measured by bioluminescence resonance energy transfer (BRET) assay...More data for this Ligand-Target Pair
TargetKelch-like ECH-associated protein 1/Nuclear factor erythroid 2-related factor 2(Human)
Senju Pharmaceutical Co.
US Patent
Senju Pharmaceutical Co.
US Patent
Affinity DataIC50: 0.530nMAssay Description:In a first step, the Keapl /compound complex was prepared by addition of 100 nL of the compound by ECHO 555, followed by 5 pL aliquots of 2x Keapl. T...More data for this Ligand-Target Pair
TargetKelch-like ECH-associated protein 1/Nuclear factor erythroid 2-related factor 2(Human)
Senju Pharmaceutical Co.
US Patent
Senju Pharmaceutical Co.
US Patent
Affinity DataIC50: 0.550nMAssay Description:In a first step, the Keapl /compound complex was prepared by addition of 100 nL of the compound by ECHO 555, followed by 5 pL aliquots of 2x Keapl. T...More data for this Ligand-Target Pair
TargetKelch-like ECH-associated protein 1/Nuclear factor erythroid 2-related factor 2(Human)
Senju Pharmaceutical Co.
US Patent
Senju Pharmaceutical Co.
US Patent
Affinity DataIC50: 0.710nMAssay Description:The inhibitory activity of each compound on the binding between NRF2 and KEAP1 was measured by bioluminescence resonance energy transfer (BRET) assay...More data for this Ligand-Target Pair
TargetKelch-like ECH-associated protein 1/Nuclear factor erythroid 2-related factor 2(Human)
Senju Pharmaceutical Co.
US Patent
Senju Pharmaceutical Co.
US Patent
Affinity DataIC50: 0.890nMAssay Description:The inhibitory activity of each compound on the binding between NRF2 and KEAP1 was measured by bioluminescence resonance energy transfer (BRET) assay...More data for this Ligand-Target Pair
TargetKelch-like ECH-associated protein 1/Nuclear factor erythroid 2-related factor 2(Human)
Senju Pharmaceutical Co.
US Patent
Senju Pharmaceutical Co.
US Patent
Affinity DataIC50: 0.900nMAssay Description:In a first step, the Keapl /compound complex was prepared by addition of 100 nL of the compound by ECHO 555, followed by 5 pL aliquots of 2x Keapl. T...More data for this Ligand-Target Pair
TargetKelch-like ECH-associated protein 1/Nuclear factor erythroid 2-related factor 2(Human)
Senju Pharmaceutical Co.
US Patent
Senju Pharmaceutical Co.
US Patent
Affinity DataIC50: 1.01nMAssay Description:The inhibitory activity of each compound on the binding between NRF2 and KEAP1 was measured by bioluminescence resonance energy transfer (BRET) assay...More data for this Ligand-Target Pair
TargetKelch-like ECH-associated protein 1/Nuclear factor erythroid 2-related factor 2(Human)
Senju Pharmaceutical Co.
US Patent
Senju Pharmaceutical Co.
US Patent
Affinity DataIC50: 1.05nMAssay Description:In a first step, the Keapl /compound complex was prepared by addition of 100 nL of the compound by ECHO 555, followed by 5 pL aliquots of 2x Keapl. T...More data for this Ligand-Target Pair
TargetKelch-like ECH-associated protein 1/Nuclear factor erythroid 2-related factor 2(Human)
Senju Pharmaceutical Co.
US Patent
Senju Pharmaceutical Co.
US Patent
Affinity DataIC50: 1.10nMAssay Description:In a first step, the Keapl /compound complex was prepared by addition of 100 nL of the compound by ECHO 555, followed by 5 pL aliquots of 2x Keapl. T...More data for this Ligand-Target Pair
TargetKelch-like ECH-associated protein 1/Nuclear factor erythroid 2-related factor 2(Human)
Senju Pharmaceutical Co.
US Patent
Senju Pharmaceutical Co.
US Patent
Affinity DataIC50: 1.15nMAssay Description:In a first step, the Keapl /compound complex was prepared by addition of 100 nL of the compound by ECHO 555, followed by 5 pL aliquots of 2x Keapl. T...More data for this Ligand-Target Pair
TargetKelch-like ECH-associated protein 1/Nuclear factor erythroid 2-related factor 2(Human)
Senju Pharmaceutical Co.
US Patent
Senju Pharmaceutical Co.
US Patent
Affinity DataIC50: 1.30nMAssay Description:The inhibitory activity of each compound on the binding between NRF2 and KEAP1 was measured by bioluminescence resonance energy transfer (BRET) assay...More data for this Ligand-Target Pair
TargetKelch-like ECH-associated protein 1/Nuclear factor erythroid 2-related factor 2(Human)
Senju Pharmaceutical Co.
US Patent
Senju Pharmaceutical Co.
US Patent
Affinity DataIC50: 1.40nMAssay Description:The inhibitory activity of each compound on the binding between NRF2 and KEAP1 was measured by bioluminescence resonance energy transfer (BRET) assay...More data for this Ligand-Target Pair
TargetKelch-like ECH-associated protein 1/Nuclear factor erythroid 2-related factor 2(Human)
Senju Pharmaceutical Co.
US Patent
Senju Pharmaceutical Co.
US Patent
Affinity DataIC50: 1.60nMAssay Description:In a first step, the Keapl /compound complex was prepared by addition of 100 nL of the compound by ECHO 555, followed by 5 pL aliquots of 2x Keapl. T...More data for this Ligand-Target Pair
TargetKelch-like ECH-associated protein 1/Nuclear factor erythroid 2-related factor 2(Human)
Senju Pharmaceutical Co.
US Patent
Senju Pharmaceutical Co.
US Patent
Affinity DataIC50: 2.30nMAssay Description:The inhibitory activity of each compound on the binding between NRF2 and KEAP1 was measured by bioluminescence resonance energy transfer (BRET) assay...More data for this Ligand-Target Pair
TargetKelch-like ECH-associated protein 1/Nuclear factor erythroid 2-related factor 2(Human)
Senju Pharmaceutical Co.
US Patent
Senju Pharmaceutical Co.
US Patent
Affinity DataIC50: 2.5nMAssay Description:TR-FRET assay was performed on a Wallac Victor 3V multi-label counter/plate reader (PerkinElmer, Shelton, CT). The plate used for the FP measurement ...More data for this Ligand-Target Pair
Ligand InfoSimilars
TargetKelch-like ECH-associated protein 1/Nuclear factor erythroid 2-related factor 2(Human)
Senju Pharmaceutical Co.
US Patent
Senju Pharmaceutical Co.
US Patent
Affinity DataIC50: 3.10nMAssay Description:The inhibitory activity of each compound on the binding between NRF2 and KEAP1 was measured by bioluminescence resonance energy transfer (BRET) assay...More data for this Ligand-Target Pair















































